Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)
Open Access
- 8 April 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (24), 2262-2271
- https://doi.org/10.1093/eurheartj/ehaa171
Abstract
Elevated lipoprotein(a) [Lp(a)] is strongly associated with an increased cardiovascular disease (CVD) risk. We previously reported that pro-inflammatory activation of circulating monocytes is a potential mechanism by which Lp(a) mediates CVD. Since potent Lp(a)-lowering therapies are emerging, it is of interest whether patients with elevated Lp(a) experience beneficial anti-inflammatory effects following large reductions in Lp(a). Using transcriptome analysis, we show that circulating monocytes of healthy individuals with elevated Lp(a), as well as CVD patients with increased Lp(a) levels, both have a pro-inflammatory gene expression profile. The effect of Lp(a)-lowering on gene expression and function of monocytes was addressed in two local sub-studies, including 14 CVD patients with elevated Lp(a) who received apolipoprotein(a) [apo(a)] antisense (AKCEA-APO(a)-LRx) (NCT03070782), as well as 18 patients with elevated Lp(a) who received proprotein convertase subtilisin/kexin type 9 antibody (PCSK9ab) treatment (NCT02729025). AKCEA-APO(a)-LRx lowered Lp(a) by 47% and reduced the pro-inflammatory gene expression in monocytes of CVD patients with elevated Lp(a), which coincided with a functional reduction in transendothelial migration capacity of monocytes ex vivo (−17%, P < 0.001). In contrast, PCSK9ab treatment lowered Lp(a) by 16% and did not alter transcriptome nor functional properties of monocytes, despite an additional reduction of 65% in low-density lipoprotein cholesterol (LDL-C). Potent Lp(a)-lowering following AKCEA-APO(a)-LRx, but not modest Lp(a)-lowering combined with LDL-C reduction following PCSK9ab treatment, reduced the pro-inflammatory state of circulating monocytes in patients with elevated Lp(a). These ex vivo data support a beneficial effect of large Lp(a) reductions in patients with elevated Lp(a).Keywords
Funding Information
- European Union’s Horizon 2020 (667837)
- The ANITSCHKOW trial (NCT02729025)
- Netherlands Heart Foundation (CVON 2011/B019, CVON 2017-20)
- Spark-Holding BV (2015B002)
This publication has 22 references indexed in Scilit:
- Effects of Extended-Release Niacin with Laropiprant in High-Risk PatientsThe New England Journal of Medicine, 2014
- Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotypeMetabolism, 2013
- Intensification of Statin Therapy Results in a Rapid Reduction in Atherosclerotic Inflammation: Results of a Multicenter Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Feasibility StudyJournal of the American College of Cardiology, 2013
- DAMPening Inflammation by Modulating TLR SignallingMediators of Inflammation, 2010
- Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary DiseaseThe New England Journal of Medicine, 2009
- Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial InfarctionJAMA, 2009
- Identification of Oxidative Stress and Toll-like Receptor 4 Signaling as a Key Pathway of Acute Lung InjuryCell, 2008
- Regulation of Interferon‐γ During Innate and Adaptive Immune ResponsesAdvances in Immunology, 2007
- Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular EventsThe New England Journal of Medicine, 2002
- Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy MenThe New England Journal of Medicine, 1997